Why the new orphan drug designation matters for Alkermes (ALKS)

The latest catalyst for Alkermes (ALKS) is the US FDA orphan drug designation for alixorexton, its phase 2 oral treatment targeting idiopathic hypersomnia. This status brings specific regulatory incentives and renewed focus on the company’s rare disease pipeline.

Alkermes’ share price has moved sharply higher in recent months, with a 30 day share price return of 18.14% and a 90 day gain of 58.14%. The 1 year total shareholder return of 48.44% points to momentum that extends beyond the latest orphan drug news, recent insider selling and the upcoming Goldman Sachs healthcare conference appearance.

If this kind of momentum in healthcare catches your eye, it could be worth widening your search using our screener of 40 healthcare AI stocks

With Alkermes trading at US$44.28, only about 4% below the average analyst price target yet flagged as significantly overvalued by at least one model, you have to ask whether there is genuine mispricing here or if the market is already assigning full credit for potential future growth.

Most Popular Narrative: 10% Overvalued

At a last close of $44.28 versus a narrative fair value of $44.24, Alkermes is framed as slightly expensive, with the story hinging on its sleep and orexin portfolio rather than legacy products.

Recent research on Alkermes reflects a mix of optimism around the sleep and narcolepsy portfolio and caution on execution, pricing assumptions, and the performance of legacy products. For you as an investor, the key themes are how analysts see the growth runway for Lumryz and the orexin program, how they frame valuation using updated models, and how they weigh the trade off between opportunity and risk in the evolving portfolio.

Want to see what sits behind that cautious optimism on the sleep franchise? The valuation hinges on specific revenue trajectories, margin shifts, and a richer future earnings multiple that reshapes what “full value” could mean for Alkermes.

Result: Fair Value of $44.24 (OVERVALUED)

However, you still need to factor in rising R&D spending on the orexin program and Alkermes’ reliance on a tight group of key products, which could put pressure on the story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another way to look at value

The narrative framework presents Alkermes as slightly expensive at a fair value of $44.24. In contrast, the SWS DCF model suggests the stock trades about 54% below an estimated future cash flow value of $95.56. For you, that is a very different story about risk and upside, so which one feels more realistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Alkermes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and concern around Alkermes resonates with you, this is the moment to review the numbers yourself and decide how the balance of risks and rewards stacks up for your portfolio, starting with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Alkermes has sharpened your focus, do not stop here, a broader watchlist of quality stocks can help you spot opportunities before they become crowded trades.

• Zero in on potential mispricing by scanning 44 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their financial profile.
• Strengthen the core of your portfolio with solid balance sheet and fundamentals stocks screener (48 results) that aim to match robust finances with dependable business models.
• Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems that sit off most radars yet still meet strict quality filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.